1. NF-κB Anti-infection Metabolic Enzyme/Protease
  2. NF-κB Bacterial HIV Endogenous Metabolite
  3. Maslinic acid

Maslinic acid  (Synonyms: Crategolic acid; 2α-Hydroxyoleanolic acid)

Cat. No.: HY-N0629 Purity: ≥98.0%
SDS COA Handling Instructions

Maslinic acid can inhibit the DNA-binding activity of NF-κB p65 and abolish the phosphorylation of IκB-α, which is required for p65 activation.

For research use only. We do not sell to patients.

Maslinic acid Chemical Structure

Maslinic acid Chemical Structure

CAS No. : 4373-41-5

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 106 In-stock
Solution
10 mM * 1 mL in DMSO USD 106 In-stock
Solid
5 mg USD 90 In-stock
10 mg USD 150 In-stock
25 mg USD 285 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

Other Forms of Maslinic acid:

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All HIV Isoform Specific Products:

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Maslinic acid can inhibit the DNA-binding activity of NF-κB p65 and abolish the phosphorylation of IκB-α, which is required for p65 activation.

IC50 & Target[1]

p65

 

Cellular Effect
Cell Line Type Value Description References
518A2 EC50
13.7 μM
Compound: 6
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 28033541]
518A2 IC50
13.7 μM
Compound: MA
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 24440377]
518A2 IC50
13.7 μM
Compound: MA
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 24361521]
518A2 IC50
13.7 μM
Compound: 1
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
[PMID: 24161703]
518A2 EC50
13.7 μM
Compound: MA
Anticancer activity against human 518A2 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human 518A2 cells measured after 96 hrs by sulforhodamine B assay
[PMID: 31330447]
518A2 EC50
13.7 μM
Compound: MA
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
518A2 EC50
13.7 μM
Compound: MA
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
518A2 EC50
13.7 μM
Compound: 3; MA
Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
8505C EC50
17 μM
Compound: 6
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
[PMID: 28033541]
8505C IC50
17 μM
Compound: MA
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
[PMID: 24440377]
8505C IC50
17 μM
Compound: MA
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
[PMID: 24361521]
8505C IC50
17 μM
Compound: 1
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
[PMID: 24161703]
8505C EC50
17 μM
Compound: MA
Anticancer activity against human 8505C cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human 8505C cells measured after 96 hrs by sulforhodamine B assay
[PMID: 31330447]
8505C EC50
17 μM
Compound: MA
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
A2780 EC50
19.5 μM
Compound: 6
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 28033541]
A2780 IC50
19.5 μM
Compound: MA
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 24440377]
A2780 IC50
19.5 μM
Compound: MA
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 24361521]
A2780 IC50
19.5 μM
Compound: 1
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
[PMID: 24161703]
A2780 EC50
19.5 μM
Compound: MA
Anticancer activity against human A2780 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human A2780 cells measured after 96 hrs by sulforhodamine B assay
[PMID: 31330447]
A2780 EC50
19.5 μM
Compound: MA
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
A2780 EC50
19.5 μM
Compound: MA
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
A2780 EC50
19.5 μM
Compound: 3; MA
Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
A549 EC50
23.4 μM
Compound: 6
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 28033541]
A549 IC50
23.4 μM
Compound: MA
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 24440377]
A549 IC50
23.4 μM
Compound: MA
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 24361521]
A549 IC50
23.4 μM
Compound: 1
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 24161703]
A549 EC50
23.4 μM
Compound: MA
Anticancer activity against human A549 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human A549 cells measured after 96 hrs by sulforhodamine B assay
[PMID: 31330447]
A549 EC50
23.4 μM
Compound: MA
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
A549 EC50
23.4 μM
Compound: MA
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
A549 EC50
23.4 μM
Compound: 3; MA
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
B16-F10 IC50
> 10 μM
Compound: I; MA
Cytotoxicity against mouse B16-F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against mouse B16-F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
[PMID: 33956447]
B16-F10 IC50
36.2 μM
Compound: MA
Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 36542806]
B16-F10 IC50
36.2 μM
Compound: II, Maslinic acid
Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay
Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay
[PMID: 29471121]
B16-F10 IC50
36.2 μM
Compound: II; MA; Maslinic acid
Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 27128174]
B16-F10 IC50
36.2 μM
Compound: 2, MA, Maslinic acid
Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay
[PMID: 24480359]
BV-2 IC50
17.8 μM
Compound: 5
Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay
Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay
[PMID: 28358502]
FaDu EC50
17 μM
Compound: MA
Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
HepG2 IC50
> 10 μM
Compound: I; MA
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
[PMID: 33956447]
HepG2 IC50
> 10 μM
Compound: 17
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 27797185]
HepG2 IC50
> 100 μM
Compound: 12
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
[PMID: 28318944]
HepG2 IC50
99.2 μM
Compound: MA
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 36542806]
HepG2 IC50
99.2 μM
Compound: II, Maslinic acid
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
[PMID: 29471121]
HepG2 IC50
99.2 μM
Compound: II; MA; Maslinic acid
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 27128174]
HSC-T6 EC50
17.3 nM
Compound: 205
Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay
[PMID: 29353722]
HT-29 IC50
> 10 μM
Compound: I; MA
Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
[PMID: 33956447]
HT-29 EC50
28.8 μM
Compound: 6
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 28033541]
HT-29 IC50
28.8 μM
Compound: MA
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 24440377]
HT-29 IC50
28.8 μM
Compound: MA
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 24361521]
HT-29 IC50
28.8 μM
Compound: 1
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 24161703]
HT-29 EC50
28.8 μM
Compound: MA
Anticancer activity against human HT-29 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human HT-29 cells measured after 96 hrs by sulforhodamine B assay
[PMID: 31330447]
HT-29 EC50
28.8 μM
Compound: MA
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
HT-29 EC50
28.8 μM
Compound: MA
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
HT-29 EC50
28.8 μM
Compound: 3; MA
Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
HT-29 IC50
32.2 μM
Compound: MA
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 36542806]
HT-29 IC50
32.2 μM
Compound: II, Maslinic acid
Growth inhibition of human HT-29 cells after 72 hrs by MTT assay
Growth inhibition of human HT-29 cells after 72 hrs by MTT assay
[PMID: 29471121]
HT-29 IC50
32.2 μM
Compound: II; MA; Maslinic acid
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 27128174]
KB IC50
> 100 μM
Compound: 12
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
[PMID: 28318944]
KB ED50
51.5 μM
Compound: 5
Cytotoxicity against human KB cells by SRB assay
Cytotoxicity against human KB cells by SRB assay
[PMID: 16562832]
Lu1 IC50
> 100 μM
Compound: 12
Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
[PMID: 28318944]
MCF7 IC50
> 10 μM
Compound: 17
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 27797185]
MCF7 IC50
> 100 μM
Compound: 12
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
[PMID: 28318944]
MCF7 EC50
> 30 μM
Compound: 6
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 28033541]
MCF7 EC50
> 30 μM
Compound: MA
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
MCF7 IC50
16.6 μM
Compound: MA
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 24361521]
MCF7 IC50
24.4 μM
Compound: 1
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 24161703]
MCF7 EC50
24.4 μM
Compound: MA
Anticancer activity against human MCF7 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human MCF7 cells measured after 96 hrs by sulforhodamine B assay
[PMID: 31330447]
MCF7 EC50
37.2 μM
Compound: MA
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
MCF7 EC50
37.2 μM
Compound: 3; MA
Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
MDCK CC50
23.3 μM
Compound: Maslinic acid
Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs
Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs
[PMID: 29394063]
NCI-N87 IC50
> 10 μM
Compound: 17
Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
[PMID: 27797185]
NIH3T3 IC50
16.6 μM
Compound: 1
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
[PMID: 24161703]
NIH3T3 IC50
16.6 μM
Compound: MA
Cytotoxic activity against mouse NIH/3T3 cells by SRB assay
Cytotoxic activity against mouse NIH/3T3 cells by SRB assay
[PMID: 26383128]
NIH3T3 EC50
16.6 μM
Compound: MA
Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by sulforhodamine B assay
[PMID: 31330447]
NIH3T3 EC50
21.1 μM
Compound: 6
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
[PMID: 28033541]
NIH3T3 IC50
21.1 μM
Compound: MA
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
[PMID: 24440377]
NIH3T3 EC50
21.1 μM
Compound: MA
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
[PMID: 30278332]
NIH3T3 EC50
21.1 μM
Compound: MA
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay
[PMID: 29529499]
NIH3T3 EC50
21.1 μM
Compound: 3; MA
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
[PMID: 27149037]
NIH3T3 IC50
21.4 μM
Compound: MA
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
[PMID: 24361521]
Sf21 IC50
> 40 μM
Compound: 11
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
[PMID: 31774676]
In Vitro

Maslinic acid (MA) inhibits LPS-induced NF-κB translocation to nucleus and phosphorylation of IκB-α. Maslinic acid has also been reported to suppress NF-κB regulated osteoclastogenesis in bone marrow monocytes and inhibit TNF-α-induced NF-κB activity and its downstream genes’ expression in pancreatic cancer cells. To confirm if the anti-inflammatory effects of olive pomace extracts (OPEs) inRAW264.7 cells can be attributed to Maslinic acid, dose-dependence experiments determined the effective concentration of Maslinic acid to be 10-20 μM. 20 μM Maslinic acid significantly suppresses TNF-α production and inhibits IL-1, IL-6, and COX-2 mRNA expression in RAW 264.7 cell. Maslinic acid (at 10 and 20 μM) significantly suppresses the DNA-binding activity of NF-κB p65 in LPS-induced RAW 264.7 cells. Pretreatment with Maslinic acid significantly reduces the LPS-induced phosphorylation of IκB-α[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Paw swelling is alleviated when mice are administered with 200 mg/kg Maslinic acid (MA), significantly suppressing inflammation, compared to the carrageenan induced control group, 4 h after λ-carrageenan injection (0.91±0.51 mm and 1.79±0.4 mm, respectively)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

472.70

Formula

C30H48O4

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@]([C@@]1([H])[C@]2(C[C@@H](O)[C@@H]3O)C)(CC[C@@]2([H])C3(C)C)[C@@](C4=CC1)(CC[C@]5(C(O)=O)[C@@]4([H])CC(C)(C)CC5)C

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (211.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1155 mL 10.5775 mL 21.1551 mL
5 mM 0.4231 mL 2.1155 mL 4.2310 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (5.29 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: ≥98.0%

References
Cell Assay
[1]

RAW 264.7 cells are seeded in 96-well culture plates at a density of 1×105 cells/mL and after incubation for 24 h, are treated with OPE1 (300 μg/mL or 400 μg/mL), OPE2 (20 μg/mL or 40 μg/mL), or Maslinic acid (10 μM or 20 μM) , as well as with/without LPS at the same time. Cell viability i determined using the WST-1 reagent. Briefly, WST-1 reagent (10 μL) is added to each well and incubated for 1h in a humidified incubator. The absorbance of the samples measured at 450 nm (reference wavelength is 750 nm). Viability is expressed as a percentage of the absorbance measured in LPS-treated cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice[1]
Five-week-old male Balb/c mice (19-21 g) are housed in a conventional condition and provided with the free access to standard rodent chow and water. Edema is induced by intraplantar injection of 100 μL 1% carrageenan into the hind left paw. Maslinic acid is tested initially at a dose of 200 mg/kg, orally administered 60 min before and after carrageenan injection. Paw thickness is measured using electronic digital calipers, 2, 3, and 4 h following carrageenan treatment. Mice are sacrificed by carbon dioxide inhalation 4 h after carrageenan injection[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1155 mL 10.5775 mL 21.1551 mL 52.8877 mL
5 mM 0.4231 mL 2.1155 mL 4.2310 mL 10.5775 mL
10 mM 0.2116 mL 1.0578 mL 2.1155 mL 5.2888 mL
15 mM 0.1410 mL 0.7052 mL 1.4103 mL 3.5258 mL
20 mM 0.1058 mL 0.5289 mL 1.0578 mL 2.6444 mL
25 mM 0.0846 mL 0.4231 mL 0.8462 mL 2.1155 mL
30 mM 0.0705 mL 0.3526 mL 0.7052 mL 1.7629 mL
40 mM 0.0529 mL 0.2644 mL 0.5289 mL 1.3222 mL
50 mM 0.0423 mL 0.2116 mL 0.4231 mL 1.0578 mL
60 mM 0.0353 mL 0.1763 mL 0.3526 mL 0.8815 mL
80 mM 0.0264 mL 0.1322 mL 0.2644 mL 0.6611 mL
100 mM 0.0212 mL 0.1058 mL 0.2116 mL 0.5289 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Maslinic acid
Cat. No.:
HY-N0629
Quantity:
MCE Japan Authorized Agent: